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Introduction: Dermal vascular smooth muscle cells (DVSMCs) are important for vascular wall fibrosis in
microangiopathy of systemic sclerosis (SSc). T helper 17 cell-associated cytokines, particularly interleukin-17A
(IL-17A), have been demonstrated to play a role in the pathogenesis of SSc. However, the effect of IL-17A on the
DVSMCs in microangiopathy of SSc has not been established. In the present study, we investigated the effect of
IL-17A on the SSc patient-derived DVSMCs.
Methods: DVSMCs from patients with SSc and healthy subjects were incubated using IL-17A or serum derived
from patients with SSc. Subsequently, the proliferation, collagen synthesis and secretion, and migration of
DVSMCs were analysed using a cell counting kit-8 (CCK-8), dual-luciferase reporter assay, real-time reverse
transcription-polymerase chain reaction (RT-PCR), Western blot, enzyme-linked immunosorbent assay (ELISA) and
transwell assay. The protein phosphorylation of signalling pathways in the process of IL-17A-mediated DVSMC
activation was investigated and validated by specific signalling pathway inhibitor.
Results: IL-17A and serum from patients with SSc could promote the proliferation, collagen synthesis and
secretion, and migration of DVSMCs. IL-17A neutralising antibody could inhibit the IL-17A-induced activation of
DVSMCs. Additionally, IL-17A induced the activation of extracellular-regulated protein kinases 1/2 (ERK1/2) in
DVSMCs, and ERK1/2 inhibitor could block the IL-17A-elicited activation of DVSMCs.
Conclusions: Our results suggested that IL-17A derived from patients with SSc might induce the proliferation,
collagen synthesis and secretion, and migration of DVSMCs via ERK1/2 signalling pathway, raising the likelihood
that IL-17A and ERK1/2 might be promising therapeutic targets for the treatment of SSc-related vasculopathy.Introduction
Systemic sclerosis (SSc) is a serious connective tissue
disease with unestablished aetiology. The pathogenesis
of SSc is microangiopathy, increasing collagen synthesis
of fibroblasts and immunological abnormality [1]. The
major clinical manifestations are local or systemic scler-
osis of skin and visceral organs, leading to high mor-
bidity and mortality rates [2]. According to the scope of
the disease, SSc can be divided into two types: diffuse cuta-
neous SSc (dcSSc) and limited cutaneous SSc (lcSSc) [3].* Correspondence: li.ming@zs-hospital.sh.cn
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unless otherwise stated.Microangiopathy is one of the earliest clinical manifes-
tations of patients with SSc, which exists throughout the
course of the disease [4]. Raynaud’s phenomenon, digital
ulcers, pulmonary arterial hypertension and renal crisis
are microangiopathy-related symptoms [5,6]. The major
pathological feature of SSc is proliferative or obstructive
vascular abnormality, involving the small arteries and ar-
terioles in the skin, lungs, heart and kidneys [7]. In the
early stage of skin lesions, the infiltrating inflammatory
cells appear primarily in the perivascular region of the
dermis layer, including CD4+ T cells and monocytes [8].
The histopathology shows vascular wall fibrosis after the
early inflammatory injury, manifesting as proliferative
vascular endothelial cells and smooth muscle cells, ins is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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skin’ [9,10].
T helper 17 (Th17) cells, a CD4+ T effector cell type, are
characterised by the predominant production of interleu-
kin 17A (IL-17A). Recent studies suggested that Th17 cells
and Th17-associated cytokines are involved in SSc [11-13].
Our previous studies have shown an increase of IL-17A in
the active phase of SSc patients. IL-17A can promote colla-
gen secretion of fibroblasts and stimulate the expressions
of intercellular adhesion molecule 1 (ICAM-1), vascular
adhesion molecule 1 (VCAM-1), chemokine (C-X-C motif)
receptor 4 (CXCR-4) and chemokine (C-C motif) ligand
20 (CCL-20) in vascular endothelial cells, resulting in
endothelial inflammation in SSc [14,15]. In addition to
causing the inflammatory response of endothelial cells,
whether IL-17A can act on dermal vascular smooth muscle
cells (DVSMCs) in the media of vascular walls has not
been established. This study elaborates the effect of IL-17A
on SSc patient-derived DVSMCs.
In the present study, we first demonstrated increased
proliferation, collagen synthesis and secretion, and mi-
gration of DVSMCs after being stimulated by human
recombinant IL-17A and SSc serum-derived IL-17A.
Furthermore, SSc serum-derived IL-17A induced the
activation of extracellular-regulated protein kinases 1/2
(ERK1/2) in DVSMCs and PD 98059 (an ERK1/2 in-
hibitor) could alleviate IL-17A-induced functional activa-
tion of DVSMCs. These data suggested that IL-17A and
ERK1/2 might play a key role in the pathophysiology of
SSc-related microangiopathy.
Methods
Patients with SSc and healthy individuals
This study was reviewed and approved by the Zhongshan
Hospital Research Ethics Committee; the human study
protocol was approved by the Institutional Review Board
of Zhongshan Hospital of Fudan University. A total of 16
patients with SSc (n = 6 men and 10 women; mean age,
43.6 ± 8.7 years) were included in the study after they pro-
vided their informed consent. All of the patients met the
American College of Rheumatology criteria for the classifi-
cation of SSc [16]. Disease activity was assessed using the
criteria proposed by Valentini et al. [17], in which the
evaluation of clinical and laboratory factors results in a
score ranging from 0 to 10 (0 represents no disease activ-
ity, and 10 represents maximal activity). All of the enrolled
patients exhibited active-stage disease with scores of ≥3,
and all of the disease durations were <5 years. All of the
patients had different degrees of clinical manifestations of
microangiopathy (for example, Raynaud’s phenomenon,
digital ulcers, telangiectasia, pulmonary hypertension and
renal crisis). In the controls, 15 age- and gender-matched
healthy individuals (n = 7 men and 8 women; mean age,
40.7 ± 6.9 years) were enrolled in our study after providinginformed consent. Blood samples were obtained from the
patients with SSc and healthy individuals. The lesional
skin tissues of patients with SSc were obtained to isolate
DVSMCs. Two normal skin tissues of age- and gender-
matched healthy subjects were obtained to isolate healthy
DVSMCs after signing informed consent forms (two tis-
sues from orthopaedic surgery).
Isolation and identification of SSc patient-derived
DVSMCs and healthy subject-derived DVSMCs
The isolation is based on a method reported by Sung
Tae Cha et al. [18]. We make some changes of the
method. Full-thickness 7-mm biopsies of about 50 mm2
in size were excised from the hand back lesions of SSc
patients and the same area of the controls. After wash-
ing the skin with phosphate-buffered solution (PBS) con-
taining 100 U/ml penicillin and 100 μg/ml streptomycin
(Invitrogen Corp, Carlsbad, CA, USA) three times for
5 min each, the tissue flap was then incubated for 2 h at
37°C in 5 mg/ml dispase solution (Invitrogen Corp). The
dermal blood vessels were isolated under a dissecting
microscope (Olympus, Tokyo, Japan). The specimens were
cut into 1 mm3 cubes and trypsinised with 0.1% trypsin
(Life Technologies, Grand Island, NY, USA) for 15 min.
Trypsin digestion was terminated using smooth muscle
cell medium-basal (Sciencecell, San Diego, CA, USA).
After removing the undigested tissues using a 200-mesh
filter (Whatman, Maidstone, UK), it was centrifuged for
10 min at 350 × g. The cell pellet was resuspended in
200 μl of PBS and layered onto a 35% Percoll solution
(Amersham Biosciences, Uppsala, Sweden). After a con-
tinuous density gradient centrifugation for 10 min at
400 × g, the smooth muscle cells have a density greater
than 1.065 g/ml. The cell band at the appropriate density
was collected and washed in PBS (Invitrogen Corp), it was
centrifuged for 10 min at 350 × g. The cell pellet was re-
suspended using smooth muscle cell medium-basal. The
cells from the third to seventh passages were identified as
smooth muscle cells using immunofluorescence staining
for smooth muscle specific α-actin (α-SMA); smooth
muscle myosin heavy chain (myosin) and calponin were
positively identified using Western blot. Furthermore, hu-
man primary dermal vascular smooth muscle cells, which
were purchased from CHI Scientific Inc (Boston, MA,
USA), served as a positive control. All cells were cultured
at 37°C with 5% CO2 and 100% humidity.
DVSMCs culture and stimulation
To investigate the effect of IL-17A derived from the serum
samples of SSc patients on DVSMCs, the cells were seeded
in 6-well plates at a density of 3 × 105 cells/well and cul-
tured overnight. Recombinant human IL-17A (eBioscience,
San Diego, CA, USA) was added into Dulbecco’s modified
Eagle’s medium (DMEM) (Hyclone, Logan City, UT, USA)
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percent of the serum of SSc patients or healthy subjects
with or without IL-17A neutralising antibody (8 μg/ml,
Abcam, Cambridge, UK) was also added into DMEM. The
cells were incubated using IL-17A, 5% SSc serum or
healthy serum for 24 h. The proliferation of cells was tested
using cell counting kit-8 (CCK-8). The collagen1α1
and collagen3α1 proximal promoter activity were de-
tected using dual-luciferase reporter gene assay (Beyotime,
Shanghai, China). The expressions of collagen 1 and colla-
gen 3 were detected using real-time RT-PCR, Western
blot and enzyme-linked immunosorbent assay (ELISA).
The migration of DVSMCs was detected using transwell
assay. For several experiments, DVSMCs were seeded in
plates at 90 to 100% confluence and incubated with IL-
17A (100 ng/ml) for 0 min, 15 min, 30 min, 45 min and
60 min. The protein of the cells was collected and the
phosphorylation status of three major protein kinases
(ERK1/2, Jun N-terminal kinase (JNK) and P38) was mea-
sured using Western blot. Moreover, the cells were stimu-
lated with 5% SSc serum, 5% healthy serum with or
without IL-17A neutralising antibody (8 μg/ml) for
30 min. Subsequently, the phosphorylation of the potential
protein kinase was surveyed using Western blot. PD
98059 (Beyotime), a specific inhibitor of ERK1/2 phos-
phorylation, and SB 203580 (Beyotime), a specific inhibitor
of p38-MAP kinase phosphorylation, were used for identi-
fying the downstream signalling mediators of the IL-17 re-
ceptor A (IL-17RA. Both PD 98059 and SB 203580 were
dissolved in dimethylsulfoxide (DMSO) (Invitrogen Corp)
at a concentration of 10 mM and added to the fresh cul-
ture medium to achieve the desired final concentra-
tions of 10 μM/ml. The cells were pretreated with PD
98059 or SB 203580 for 2 h and then incubated using IL-
17A (100 ng/ml), 5% serum from the patients with SSc or
5% serum from the healthy controls for 24 h.
CCK-8
According to the manufacturer’s instructions, CCK8
(KeyGEN, Nanjing, Jiangsu, China) was used to measure
the proliferation of DVSMCs. First, 2 × 103 cells were
plated in a volume of 100 μl into each well of 96-well
plates. All assays were performed in quadruplicate. When
cells were grown to 90 to 100% confluence, they were
given various stimulations for 24 h, 48 h and 72 h. After
this incubation period, an orange soluble formazan prod-
uct formed. The formazan product was spectrometrically
quantified using an ELISA reader (Molecular Devices,
Sunnyvale, CA, USA) (λ = 450 nm).
Dual-luciferase reporter assay
The collagen1α1 proximal promoter sequences (contain-
ing −174 bp to +42 bp) [19] or collagen3α1 proximal
promoter sequences (containing −96 bp to −34 bp) [20]were cloned into pGL3-basic vector (Promega, Madison,
WI, USA), leading to the construction of two recombinant
plasmids. The inserts were confirmed by DNA sequen-
cing. DVSMCs were transiently transfected at 95% conflu-
ence with the recombinant plasmids by Lipofectamine
2000 (Life Technologies), and pRL-SV40 (Promega) was
used to normalize the transfection efficiency. Four hours
after transfection, the medium was replaced with different
concentrations of IL-17A, 5% serum from the patients
with SSc or 5% serum from the healthy controls in
DMEM. Luciferase activity was tested after 24 h in-
cubation using the dual-luciferase reporter assay system
(Beyotime). The ratio of Firefly luciferase to Renilla lucifer-
ase activity was calculated to correct transfection effi-
ciency and cell numbers of each well. For each plasmid,
three independent transfection experiments were per-
formed, and each was done in triplicate.
Real-time RT-PCR
Total RNA of DVSMCs was extracted with TRIzol re-
agent (Life Technologies). Complementary DNA (cDNA)
samples were synthesized using the First Strand cDNA
Synthesis Kit and oligo(dT) primers (Thermo Fisher
Scientific, Waltham, MA, USA). Levels of mRNA for
particular genes were examined using SYBR Green PCR
Master Mix (Takara, Otsu, Japan). The following primer
pairs were used: Hum Collagen 1, forward GTTGTG
CGATGACGTGATCTGTGA and reverse TTCTTGG
TCGGTGGGTGACTCTG; Hum Collagen 3, forward
GCTGGCTACTTCTCGCTCTG and reverse TCCGCA
TAGGACTGACCAAG; GAPDH, forward GGGGCTC
TCCAGAACATCATCC and reverse ACGCCTGCTT
CACCACCTTCTT.The 2-ΔΔCt method was used to nor-
malise transcription to GAPDH and to calculate the fold
induction relative to controls.
ELISA
The concentrations of collagen 1 and collagen 3 in the
culture supernatants of DVSMCs were detected using
the ELISA kit (USCN Life Science, Wuhan, Hubei,
China) according to the manufacturer’s instructions.
Standard protein samples and culture supernatants were
incubated for 2 h at room temperature. After washing
four to six times, each well was incubated using 50 μl
primary anti-human collagen 1 and collagen 3 antibodies
for 1 h, respectively. After washing as previously, 100 μl
enzyme-labelled antibodies were added into each well
and incubated for 1 h at room temperature. Subse-
quently, solutions A and B were mixed 1:1 and added to
each well. Half an hour later, the reaction was termi-
nated by 50 μl buffer. Collagen 1 and collagen 3 concen-
tration data were presented as the means ± standard
deviation. The assay was performed in triplicate accord-
ing to the manufacturer’s recommendations.
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The proteins of DVSMCs were extracted using RIPA
lysis buffer (Beyotime), with the protease inhibitor phe-
nylmethanesulfonyl fluoride (Beyotime). The proteins
were separated into 8% or 10% SDS-PAGE (Beyotime),
and then transferred onto PVDF membranes (EMD
Millipore, Billerica, MA, USA). After being blocked with
5% milk for 2 h at room temperature, the membranes were
incubated using primary antibodies, including rabbit anti-
human collagen 1 (1:1000, Abcam), rabbit anti-human col-
lagen 3 (1:3000, Abcam), rabbit anti-human α-SMA (1:600,
Abcam), goat anti-human IL-17RA (1:1000, Abcam), rabbit
anti-human p38 (1:1000, Cell Signaling Technology,
Boston, MA, USA), rabbit anti-human phospho-p38 MAPK
(1:1000, Cell Signaling Technology), rabbit anti-human JNK
(1:1000, Cell Signaling Technology), rabbit anti-human
phospho-JNK (1:1000, Cell Signaling Technology), rabbit
anti-human ERK1/2 (1:1000, Cell Signaling Technology),
rabbit anti-human phospho-ERK1/2 (1:1000, Cell Signaling
Technology), and rabbit anti-human GAPDH (1:1000, Cell
Signaling Technology) overnight at 4°C. The membranes
were then washed and incubated with appropriate HRP-
conjugated secondary antibodies for 1.5 h at room
temperature. The proteins were detected using ECL detec-
tion reagents (Beyotime).
Transwell
The migration assay of DVSMCs was performed using
polycarbonate membrane transwell inserts (8 μm pore
size) (Corning, New York, NY, USA). The cells that
exhibited growth arrest for 48 h were harvested with
0.05% trypsin-EDTA (Life Technologies) and resuspended
(10 × 105 cells/ml) with serum-free DMEM. The cells were
added into the upper chamber. IL-17A (100 ng/ml), 5%
healthy serum, 5% SSc patient-derived serum with or
without neutralising antibody, PD9 8059 or SB 203580
was added into the lower chamber. The cells were incu-
bated for 6 h at 37°C and 5% CO2. After scraping the cells
affixed to the inside of the membrane, the cells that had
migrated through the insert were fixed with 4% parafor-
maldehyde (Beyotime) and stained with Giemsa (Jiancheng
Bioengineering Research Institute, Nanjing, Jiangsu, China)
according to the manufacturer’s instructions. For each well,
the number of migrated cells was counted from five high-
power fields (HPF) at 200 ×magnification.
Statistical analysis
The quantitative data are expressed as the means ±
standard deviation. Statistical analysis was performed
using SPSS 17.0 statistical software (SPSS Inc., Chicago,
IL, USA). Statistical significance was determined using
analysis of variance followed by Student’s t test for com-
parisons of multiple means. The results showing P <0.05
were considered to be statistically significant.Results
IL-17A promotes the proliferation of SSc patient-derived
DVSMCs
Previous studies have demonstrated thickened dermal
vascular walls in the histopathology of systemic sclero-
derma [21,22]. In the media of the vascular walls,
smooth muscle cells apparently proliferate. Our recent
study observed that IL-17+ lymphocytes infiltrated the
vascular walls and perivascular regions, especially in the
dermis layer [15]. To investigate the effect of IL-17A
on the proliferation of SSc patient-derived DVSMCs,
DVSMCs were first isolated from the skin of SSc pa-
tients and healthy donors. The expressions of myosin,
calponin, α-SMA and IL-17RA were detected using the
Western blot or immunofluorescence (See Additional
file 1: Figure S1A, B; Additional file 2: Figure S2A-E).
The cells were treated with different concentrations of
IL-17A for 24 h, 48 h and 72 h. We observed a signifi-
cant proliferation of SSc patient-derived DVSMCs after
incubation with IL-17A (100 ng/ml) for 72 h compared
with the vehicle (Figure 1A). A similar proliferative re-
sponse was observed in the cells incubating with 5% SSc
serum (Figure 1B) for 72 h. Pretreatment using IL-17
neutralising antibody, but not its isotype control, inhibited
IL-17A-induced proliferation of DVSMCs (Figure 1A,B).
Altogether, our results suggested that IL-17A derived from
the serum of patients with SSc might stimulate the prolif-
eration of SSc patient-derived DVSMCs.
IL-17A induces the collagen synthesis and secretion of
SSc patient-derived DVSMCs
We investigated the role of IL-17A on the collagen 1
and collagen 3 synthesis and secretion of SSc patient-
derived DVSMCs, which are the major components of
the vascular wall media. In Th17 cytokine families, IL-
17A is identified as the key cytokine associated with
autoimmunity, inflammation and host defence [23].
However, it is unknown whether IL-17A can promote
collagen 1 and collagen 3 synthesis and secretion of SSc
patient-derived DVSMCs. In the present study, we first
examined the effect of IL-17A on collagen1α1 and col-
lagen3α1 proximal promoter activity by construction of
reporter gene plasmids and dual-luciferase reporter gene
assay. The results showed that collagen1α1 and col-
lagen3α1 proximal promoter activity significantly enhanced
after being stimulated by human recombinant IL-17A
(Figure 1C) and SSc serum-derived IL-17A (Figure 1D).
Second, the mRNA of collagen 1 and collagen 3 were also
increased after being incubated with IL-17A (Figure 1E)
and SSc serum-derived IL-17A (Figure 1F). Third, when
IL-17A alone was used to stimulate SSc patient-derived
DVSMCs, Western blot demonstrated that the expres-
sions of collagen 1, collagen 3 and α-SMA were increased
(Figure 1C). Furthermore, it also showed that 5% serum of
Figure 1 IL-17A derived from SSc patient serum promotes the proliferation, collagen synthesis and secretion of SSc patient-derived
DVSMCs. (A) DVSMCs were treated with different doses of IL-17A for 24 h, 48 h, 72 h, and cell proliferation was tested using cell counting kit-8.
(B) The cells were treated with the serum of SSc patients for 24 h, 48 h, 72 h, and cell proliferation was tested using CCK8. (C) The activity of
collagen1α1 or collagen3α1 proximal promoter was test using a dual luciferase reporter gene assay after being treated with different doses of
IL-17A for 24 h. (D) The activity of collagen1α1 or collagen3α1 proximal promoter was also detected after being treated with the serum of SSc
patients and healthy subject for 24 h. Data were represented as mean ratios of Firefly to Renilla luciferase activity. (E) The cells were cultured in
the indicated doses of IL-17A for 24 h, the gene expression of collagen 1 and collagen 3 was measured using real-time RT-PCR analysis. (F) The cells
were stimulated with the serum of SSc patients and healthy subjects for 24 h, and the gene expression of collagen 1 and collagen 3 was measured
using real-time RT-PCR analysis. (G) The cells were treated with different doses of IL-17A for 24 h, the concentration of collagen 1, collagen 3 was
detected using ELISA. (H) The cells were treated with the serum of SSc patients and healthy subjects for 24 h, and the concentration of collagen 1,
collagen 3 was also detected by ELISA. (I, J) The cells were treated with different doses of IL-17A, serum of SSc patients or healthy individuals for 24 h,
and the expressions of collagen 1, collagen 3, IL-17RA and α-SMA were measured using Western blot. GAPDH was used as a loading control. The
experiment was repeated three times, and the data are presented as means ± standard deviation.
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gen 3 and α-SMA of DVSMCs, and the neutralisation
of IL-17A in the culture medium suppressed the ex-
pressions of these proteins (Figure 1D). Additionally,
we observed that the secretions of collagen 1 and collagen
3 were increased when SSc patient-derived DVSMCs were
incubated with 5% SSc serum and different doses of IL-
17A (Figure 1E,F). The IL-17A neutralising antibody
counteracted the effect of IL-17A on SSc patient-derived
DVSMCs (Figure 1E,F). Altogether, these results implied
that IL-17A derived from the serum of SSc patients might
have a potential role in inducing collagen synthesis and se-
cretion of SSc patient-derived DVSMCs.IL-17A stimulates the activation of SSc patient-derived
DVSMCs via ERK phosphorylation
The results of the above experiments show that IL-17A de-
rived from SSc serum promotes the proliferation, collagen
synthesis and secretion of SSc patient-derived DVSMCs;
however, the precise mechanisms underlying these effects
have not been established. According to the literature, the
mitogen-activated protein kinase (MAPK) signalling pathway
may be involved in IL-17-mediated inflammation of coronary
smooth muscle cells and human umbilical vein endothelial
cells [15,24]. To explore the potential involvement of protein
kinase pathways in IL-17A-mediated proliferation, collagen
synthesis and secretion of SSc patient-derived DVSMCs, we
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ERK1/2 in these cells using Western blot. A prominent in-
crease of phospho-ERK1/2 MAPK level was observed in SSc
patient-derived DVSMCs after stimulation with IL-17A
(100 ng/ml) (Figure 2A). Additionally, the increased
expression of phospho-ERK1/2 was detected when cells
were exposed to serum from patients with SSc. Moreover,
IL-17 neutralising antibody and PD 98059 (ERK1/2 inhibi-
tor) could weaken the expression of phospho-ERK1/2
MAPK (Figure 2B-D). These experiments revealed that the
ERK1/2 MAPK might be an important signalling pathway
in IL-17A-induced activation of DVSMCs.
To elucidate the role of the ERK1/2, PD 98059 (ERK1/
2 inhibitor) and SB 203580 (P38 inhibitor) were used to
treat SSc patient-derived DVSMCs in the presence of
IL-17A or serum from patients with SSc. PD98059 sig-
nificantly attenuated IL-17A-mediated upregulation of
proliferation, collagen synthesis and secretion of these
cells (Figure 3A-J). These results indicated that ERK1/2
signalling pathway might play a key role in IL-17A-
induced proliferation, collagen synthesis and secretion of
SSc patient-derived DVSMCs.
IL-17A induces the migration of SSc patient-derived
DVSMCs
Our previous study showed that IL-17A facilitated the
adhesion of T cells or peripheral blood mononuclearFigure 2 IL-17A induces ERK1/2 MAPK phosphorylation in SSc patient
100 ng/ml IL-17A for 15, 30, 45 and 60 min, and the phosphorylation of ER
cells were exposed to the serum of SSc patients or healthy controls for 30
by Western blot. (C) The cells were incubated with IL-17A (100 ng/ml) in th
ERK1/2 was detected using Western blot. (D) The cells were incubated with 5
for 30 min, the phosphorylation of ERK1/2 was detected using Western blot. G
times. DVSMCs, dermal vascular smooth muscle cells; ELISA, enzyme-linked im
interleukin-17A; JNK, Jun N-terminal kinase; MAPK, mitogen-activated proteincells (PBMCs) to vascular endothelial cells by co-culture
of Jurkat cells or SSc patient-derived PBMCs with hu-
man umbilical vein endothelial cells [15]. Cell adhesion
and migration were two interrelated biological processes.
In the present study, we investigated the effect of IL-
17A on the migration of SSc patient-derived DVSMCs.
We found that after stimulation by IL-17A (100 ng/ml)
and 5% SSc serum, the number of migrated cells in-
creased significantly (P <0.05) compared with negative
controls (Figure 4A,B). IL-17A neutralising antibody or
PD 98059 reduced the number of migrated cells (P <0.05)
(Figure 4A,B). These results indicated that IL-17A might
promote the migration of SSc patient-derived DVSMCs via
the ERK1/2 signalling pathway.
Discussion
There is growing recognition that Th17 cells are in-
volved in a variety of human diseases, for example, sys-
temic lupus erythematosus (SLE), psoriasis, rheumatoid
arthritis, multiple sclerosis, colitis, atherosclerosis, asthma,
and particularly autoimmune diseases [25-33]. Moreover,
increasing evidence suggests that IL-17-producing cells
are related to SSc, in which Th17 cells and characteristic
cytokines increase significantly [34]. Furthermore, Th17
cytokines have been observed to be associated with the ac-
tivity of SSc [14,35]. IL-17A may induce endothelial in-
flammation in SSc [15]. To the best of our knowledge,-derived DVSMCs. (A) SSc patient-derived DVSMCs were treated with
K1/2, p38 MAPK and JNK were detected using Western blot. (B) The
min, the phosphorylation of ERK1/2, p38 MAPK and JNK were detected
e presence of PD98059 (10 μM/ml) for 30 min, the phosphorylation of
% SSc serum or healthy serum in the presence of PD98059 (10 μM/ml)
APDH was used as a loading control. The experiment was repeated three
munosorbent assay; ERK, extracellular-regulated protein kinases; IL-17A,
kinases; SSc, systemic sclerosis.
Figure 3 IL-17A induces proliferation, collagen synthesis and secretion of SSc patient-derived DVSMCs via ERK1/2 signing pathway. (A)
DVSMCs were pre-treated with PD 98059 (10 μM/ml) for 2 h before incubation with IL-17A at 100 ng/ml for 24 h, 48 h, 72 h, and cell proliferation was
tested using cell counting kit-8. (B) The cells were pre-treated with PD98059 for 2 h before incubation with the serum of SSc patients or healthy
individuals for 24 h, 48 h, 72 h, and cell proliferation was tested using CCK8. (C) The cells were pre-treated with PD 98059 for 2 h before incubation
with IL-17A at 100 ng/ml for 24 h. The activity of collagen1α1 or collagen3α1 proximal promoter was detected using a dual luciferase reporter
gene assay. (D) After being pre-treated with PD98059 for 2h before incubation with the serum of SSc patients or healthy individuals for 24 h,
the activity of collagen1α1 or collagen3α1 proximal promoter was also detected. Data were represented as mean ratios of Firefly to Renilla luciferase
activity. (E, F) The cells were pre-treated with PD 98059 for 2 h before incubation with IL-17A or SSc serum for 24 h, the gene expression of collagen 1
and collagen 3 was measured using real-time RT-PCR analysis. (G, H) The cells were pre-treated with PD 98059 for 2 h before incubation with IL-17A
or SSc serum for 24 h, the concentration of collagen 1, collagen 3 was detected using ELISA. (I, J) The cells were pre-treated with PD98059 for 2 h
before incubation with IL-17A, serum from SSc patients and healthy individuals for 24 h, and the protein expressions of collagen 1, collagen 3, IL-17RA
and α-SMA were measured using Western blot. GAPDH was used as a loading control. The experiment was repeated three times, and the data are
presented as means ± standard deviation.
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SSc patient-derived DVSMCs.
Because of the importance of the Th17 cytokine family
in SSc, we aimed to explore the relationship between
these cytokines and SSc patient-derived DVSMCs, which
was the potential factor for vascular wall thickening. In
the present study, we confirmed that Th17 cytokines
might promote the proliferation of SSc patient-derived
DVSMCs for the first time. IL-17A enhanced theproliferation of SSc patient-derived DVSMCs in a dose-
and time-dependent fashion compared with healthy
DVSMCs (See Additional file 3: Figure S3A, B). The
peak proliferation was at 100 ng/ml within 72 h. These
cells also proliferated apparently after being stimulated
by SSc serum. IL-17A neutralising antibody inhibited
IL-17A-induced proliferation of SSc patient-derived
DVSMCs. These results were consistent with other
studies concerning asthma, which revealed that Th17-
Figure 4 IL-17A promotes migration of SSc patient-derived DVSMCs by ERK signalling pathway. (A) SSc patient-derived DVSMCs were
incubated with IL-17A (100 ng/ml), 5% healthy serum, 5% SSc serum with or without anti-IL-17A antibody (8 μg/ml), ERK inhibitor (PD98059,
10 μM/ml) or P38 inhibitor SB 203580 (10 μM/ml) for 24 h. Black arrows represent migrated cells in per high-power field (HPF) at 200 ×magnification.
Scale bar = 100 μm. (B) The number of migrated cells in per HPF. The experiment was repeated three times, and the data are presented
as mean ± standard deviation. DVSMCs, dermal vascular smooth muscle cells; ELISA, enzyme-linked immunosorbent assay; ERK, extracellular-regulated
protein kinases; IL-17A, interleukin-17A; SSc, systemic sclerosis.
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muscle cell proliferation [33].
In addition to cell proliferation, we examined IL-17A-
mediated collagen synthesis and secretion from SSc
patient-derived DVSMCs. We stimulated cells using
different concentrations of IL-17A and SSc serum, collagen
synthesis and secretion were tested using dual-luciferase
reporter assay, real-time RT-PCR, Western blot and
ELISA. Collagen 1 and collagen 3 of SSc patient-derived
DVSMCs increased at promoter, mRNA and protein levels
compared with healthy DVSMCs (See Additional file 3:
Figure S3B-J). Moreover, our study showed that IL-17A
promoted the migration of SSc patient-derived DVSMCs.
We speculated that IL-17A might promote the migration
of vascular smooth muscle cells from the vascular mediato the intima, resulting in intimal thickening, which is simi-
lar to their role in atherosclerosis. The migration of vascu-
lar smooth muscle cells is one of the key factors that
contribute to atherosclerosis; many growth factors and
chemotactic factors are involved in this process.
Mitogen-activated protein kinases (MAPKs), a class of
serine/threonine protein kinases, include ERK, c-JNK
and p38 MAPK. Several studies have demonstrated that
MAPKs signal transduction pathways are present in the
majority of cells, inducing cell proliferation, differenti-
ation, transformation and apoptosis [36-38]. Studies have
reported that the ERK pathway might be associated with
airway smooth muscle cell proliferation of asthma pa-
tients [39]. IL-17A promotes the migration of asthma
patient-derived smooth muscle cells through p38-MAPK
Liu et al. Arthritis Research & Therapy  (2014) 16:4223 Page 9 of 10signalling pathways. However, how the signalling path-
way of IL-17A induced the functional activation of SSc
patient-derived DVSMCs remains unclear. In the present
study, we found that the treatment of SSc patient-
derived DVSMCs using IL-17A resulted in increased
phosphorylation of ERK1/2, but not p38-MAPK or JNK.
Additionally, ERK1/2 inhibitor (PD98059) significantly
inhibited IL-17A-mediated proliferation, collagen synthesis
and secretion, and migration of SSc patient-derived
DVSMCs. These data suggest that ERK1/2 phosphoryl-
ation may play a key role in IL-17A-induced dysfunction of
SSc patient-derived DVSMCs.
One of the advantages of this study is the ability
to analyse the effect of IL-17A on SSc patient-derived
DVSMCs, which shows that IL-17A derived from the
serum of SSc patients has the capability of enhancing
proliferation, collagen synthesis and secretion, and mi-
gration. This effect may be dependent on the ERK1/2
MAPK signalling pathway.
Conclusions
Altogether, our data raise the likelihood that Th17 cyto-
kines may play a role in vascular wall remodelling and
provide evidence of a new mechanism that may involve
vascular fibrosis in patients with SSc. Thus, targeting the
control of ERK activation may provide a new therapeutic
approach for the treatment of microangiopathy of SSc.
However, whether this hypothesis is valid in vivo re-
quires additional investigation.
Additional files
Additional file 1: Figure S1. The morphology and identification of SSc
patient-derived DVSMCs. (A) The morphology and positive marker
(α-SMA, green fluorescence) of SSc patient-derived DVSMCs were shown.
(B) Myosin, calponin, α-SMA and IL-17RA expression in SSc patient-derived
DVSMCs and human primary dermal vascular smooth muscle cells
(HDVSMCs) were examined by means of western blot assay. GAPDH was
used as a loading control.
Additional file 2: Figure S2. The morphology and identification of
healthy subject-derived DVSMCs. The morphology and positive markers
(myosin, red fluorescence; calponin, green fluorescence) of healthy
subject-DVSMCs were shown. Myosin and calponin were detected using
double immunofluorescence staining.
Additional file 3: Figure S3. The effect of IL-17A on healthy subject-
derived DVSMCs. (A) Healthy subject-derived DVSMCs were treated with
different doses of IL-17A for 24 h, 48 h, 72 h, and cell proliferation was
detected using CCK8. (B) The cells were treated with the serum of SSc
patients and healthy subject for 24 h, 48 h, 72 h, and cell proliferation
was detected using CCK8. (C, D) A dual luciferase reporter gene assay
with a short fragment of the collagen1α1 or collagen3α1 proximal pro-
moter was performed in the cells after being treated with different doses
of IL-17A, the serum of SSc patients or healthy subjects for 24 h. (E, F)
The cells were cultured in the indicated doses of IL-17A, the serum of SSc
patients or healthy subjects for 24 h, the gene expression of collagen 1
and collagen 3 was measured using real-time PCR analysis. (G, H) The
cells were treated with different doses of IL-17A, the serum of SSc patients or
healthy subjects for 24 h, and the concentration of collagen 1 and collagen 3
in supernatants was detected using ELISA. (I, J) The cells were treated withdifferent doses of IL-17A and serum of SSc patients and healthy individuals
for 24 h, and the protein expression of collagen 1, collagen 3 and α-SMA was
measured using Western blot. GAPDH was used as a loading control. (K) The
cells were incubated with IL-17A, healthy serum, SSc serum with or without
anti-IL-17A antibody (8 μg/ml) for 24 h. Black arrows represent magrated cells
in per high-power field at 200 ×magnification. Scale bar = 100 μm. The ex-
periment was repeated three times, and the data are presented as means ±
standard deviation.
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